Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Dissociative

or Opioid

or Sedative-hypnotic

Use the filters below to narrow your results.

Other values:

None (38)

GABAA positive allosteric modulator (15) · Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (3) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · NMDA antagonist (3) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

None (79) · Mild to moderate pain; cough suppression (low-dose). (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (79) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (79) · 28 mg/device (each dose uses 2 devices) (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (79) · 360 mg/day (1) · 84 mg per session (1) · N/A (never approved) (1)

None (79) · Intranasal (under direct medical supervision) (1) · intranasal; rectal and IV reported. (1) · Oral (1) · PO (only formulation marketed in the US). (1) · sublingual (1)

None (79) · 30–60 min (PO) (1) · Within hours of first administration (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (79) · 4–6 hours (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (79) · 2.5–3 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~7-12 hours (1)

None (79) · Not formally characterized in humans. (1) · ~48% intranasal (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (79) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Avoid; may cause fetal harm (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (80) · Rx, Schedule III (US). REMS program required. (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 82 results in range #1 to #82.

2

2-FDCK

3

4

4-MeO-PCP

7

7-Hydroxymitragynine

A

B

C

D

E

F

G

H

I

Ibogaine

K

Kratom

L

M

N

O

P

Q

Quazepam

R

S

T

U

U-47700

X

Xenon

Z

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"